Newton Fund - Development of an oral, thermostable enteric fever vaccine: saving lives and supporting tourism in Mexico

肠道发热是由两种细菌引起的：伤寒沙门氏菌（伤寒）和副伤寒沙门氏菌（副伤寒），从受污染的食物或水感染。虽然有预防伤寒的疫苗，但副伤寒却没有疫苗，副伤寒是一个全球性的日益严重的问题。全球每年有近2700万例肠热病病例，该项目开发的伤寒副伤寒双重疫苗Entervax™不仅可以造福墨西哥社会，还可以造福发展中国家的人口和全球旅行者。该项目将英国Prokarium的新型疫苗输送技术与墨西哥Probiomed的制药能力结合在一起。Entervax™疫苗被吞咽，通过胃进入肠道，在那里释放安全的细菌以靶向人体自身的免疫细胞并引发免疫反应以防止肠热病。这避免了注射的需要，更重要的是，它可以提供给生活在偏远地区的人，因为疫苗是自我管理的。如果未来的疫苗是为墨西哥的市场供应而生产的，这将在制药行业创造和支持许多高技能的工作。

Enteric fever is caused by two types of bacteria: Salmonella Typhi (typhoid) and Salmonella Paratyphi (paratyphoid), contracted from contaminated food or water. Although there are vaccines to prevent typhoid, there is no vaccine for paratyphoid which is a growing problem globally. With nearly 27 million global cases of enteric fever each year, Entervax™, the dual typhoid-paratyphoid vaccine developed in this project, could profit not only the Mexican society but also populations in developing countries and travellers globally. This project brought together UK-based Prokarium’s novel vaccine delivery technology with Mexican Probiomed’s pharmaceutical manufacturing capability. The Entervax™ vaccine is swallowed, passes through the stomach and into the intestine where safe bacteria are released to target the body’s own immune cells and trigger an immune response to protect against enteric fever. This avoids the need for injections, and more importantly means it can be delivered to people living in remote areas, as the vaccine is self-administered. If the future vaccine is manufactured for market supply in Mexico, this would generate and support many highly skilled jobs in the pharmaceutical industry.